The Risky Research Review Act would create an independent Life Sciences Research Security Board inside the Executive Branch to review proposed and ongoing federal funding for life sciences research. The Board would determine whether projects meet criteria for high-risk life sciences research and would issue binding determinations that agencies must follow.
The bill also establishes appointment and ethics rules for Board members, requires attestation and disclosure from funding recipients, and sets up a reporting and auditing framework to monitor compliance.
The core aim is to introduce centralized risk assessment and oversight for life sciences research with potential public health or national security implications. Supporters argue the framework would prevent harmful misuse of research, while critics warn it could slow legitimate scientific progress and create new compliance burdens for universities and research bodies.
At a Glance
What It Does
Establishes the Life Sciences Research Security Board within subtitle V of title 31 to review federal funding for high-risk life sciences research and to issue binding determinations on whether funding may proceed. It defines high-risk research, requires agency referrals, and empowers the Board to request information and regulate review processes.
Who It Affects
Federal funding agencies, universities and research institutes applying for high-risk life sciences funding, principal investigators, biosafety officers, and researchers handling select agents or toxins; the Board and Executive Director as the governing authority.
Why It Matters
Creates a formal risk-management gate for life sciences funding, aiming to limit misuse of dual-use research and high-consequence pathogens while standardizing oversight across agencies and recipients.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a Life Sciences Research Security Board as an independent federal body in the Executive Branch. Its job is to review federal funding proposals and ongoing life sciences projects that could pose significant public health or national security risks.
The Board’s reviews are binding on the funding agencies, meaning agencies must delay or deny funding if the Board determines a proposal is too risky or if ongoing work requires a pause until risk assessments are completed.
The Board would have defined definitions for terms like dual-use research of concern, high-consequence pathogens, and gain-of-function research, and would oversee a process for assessing and managing risks across life sciences disciplines. It would set up appointment rules for nine members (including an Executive Director), establish security clearances, and require ethics reviews to manage conflicts of interest.
Agencies seeking funding would attest to whether the proposed work is high-risk and disclose support, while ongoing projects could be paused if found to pose unacceptable risks. The statute also creates reporting obligations, annual oversight by the GAO, and a specific budget authorization to fund the Board’s work.In sum, the Act embeds a centralized risk-review mechanism into federal funding decisions for life sciences, with the aim of preventing dangerous research while balancing the need for scientific advancement and national security.
The Five Things You Need to Know
The Board is created as an independent agency within the Executive Branch to review high-risk life sciences funding.
There will be 9 Board members: 5 scientists, 2 security experts, 1 biosafety expert, plus an Executive Director.
Federal funding for high-risk life sciences research cannot proceed without Board approval.
Recipients must attest to whether their work is high-risk and disclose funding sources if applicable.
GAO will audit the Board periodically, and the Act authorizes $30 million per year from 2026 to 2035.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Definitions and terms
This section defines core terms that guide the Board’s jurisdiction: what constitutes an “agency” for purposes of Board reviews, who counts as an “Executive Director” or “Board,” what is meant by “dual use research of concern,” “high-consequence pathogen,” “gain of function research,” and “life sciences research.” It also defines “Federal funding,” “select agent or toxin,” and related categories to enable precise scoping of the Board’s review authority.
Board establishment and appointment
There is established a Life Sciences Research Security Board within the Executive Branch. The President appoints 9 US citizens for up to two 4-year terms, including the Executive Director, five nongovernmental life sciences scientists, two nongovernmental national security experts, and one nongovernmental biosafety expert. The section sets qualification standards and limitations, including conflicts of interest and restrictions on prior employment in certain defense and intelligence agencies.
Executive Director and staff
This provision lays out the appointment of the Executive Director by the President (with Senate advice and consent) for a 4-year term, including requirements for independence, bioscience prominence, and prior disqualification from active federal employment. It also covers staff appointments (up to 25), security clearances, and the Executive Director’s duties as chair and administrator of Board operations.
Board mission, powers, and procedures
The Board’s mission is to issue binding determinations on whether agencies may award funding for high-risk life sciences research. It can regulate its own procedures, establish review processes for preaward funding, require agencies to share information (including classified or protected data), and issue regulations to govern Board decisions. It also outlines initial requirements for procedural publication and congressional consultation.
Preaward referrals and attestation
Agencies must refer high-risk life sciences funding proposals to the Board before award and wait for the Board’s final determination. Applicants must attest to whether proposed work is high-risk and disclose funding sources if active select agents or toxins are involved. Agencies must integrate Board processes into preaward and postaward workflows and maintain records for audits.
Review process and considerations
This is the core review mechanism: the Board reviews high-risk life sciences funding proposals or ongoing work, issues determinations about necessary biosafety and biosecurity controls, and may require withholding or altering funding. It directs factors to consider, including public health risk, national security, benefits versus risks, foreign involvement, information risks, and alternatives with lower risk. It also covers notice, meeting requests, and potential expedited review for emergencies.
GAO oversight
The Comptroller General conducts periodic audits of the Board to assess effectiveness, efficiency, and compliance with statutory requirements. This ensures accountability and provides the Congress with independent performance feedback.
Funding and appropriation
The Act authorizes $30,000,000 for each fiscal year 2026 through 2035 to fund the Board’s activities, including staff, security clearances, information-sharing capabilities, and compliance activities.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Universities, research institutions, and their sponsored programs offices gain a clear, binding review pathway for high-risk funding decisions, potentially reducing ambiguous risk assessments.
- Federal funding agencies (e.g., DOD, HHS agencies, DHS) obtain binding Board determinations that standardize risk assessment and can prevent misaligned funding.
- Principal investigators and biosafety officers at research sites benefit from defined criteria and oversight, which may reduce ad hoc risk judgments and enhance safety planning.
- Biosecurity and biosafety communities gain formal mechanisms to identify and mitigate high-risk research and to improve accountability in life sciences funding.
- Congressional oversight committees receive structured reporting and visibility into risk management practices across federal life sciences funding.
Who Bears the Cost
- Universities and research institutions face additional administrative requirements, attestations, and potential delays in funding as Board reviews are conducted.
- Federal agencies must allocate resources to prepare, submit, and respond to Board requests for information and to implement Board determinations.
- Researchers performing high-risk work may experience tighter controls and more frequent reporting, potentially slowing research timelines.
- Contractors and subcontractors are subject to disclosure and audit requirements, increasing compliance obligations.
- Smaller or under-resourced labs may bear a disproportionate burden from enhanced governance and information-sharing requirements.
Key Issues
The Core Tension
The central tension is between stringent risk mitigation and the need to preserve scientific innovation. The Board’s authority to halt or alter funding based on risk criteria could slow promising research, while too lax a standard could fail to prevent dangerous work. Balancing transparency, ethics, and national security with scientific autonomy is the fundamental policy dilemma of this bill.
The bill’s design centralizes risk assessment for high-risk life sciences and imposes a formal gatekeeping process on federal funding. This creates a clearer line of authority for evaluating whether research could pose health, safety, or national security risks.
However, it also introduces potential delays to funding and research timelines, adds administrative demands on researchers and institutions, and raises questions about how risk is defined and applied across diverse life sciences fields. The interplay between secrecy (classified information sharing), transparency (public reporting), and accountability (oversight by Congress and GAO) requires careful calibration to avoid hindering legitimate scientific progress while maintaining safety and security standards.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.